Rajeshwar Reddy Kasarla¹*, Rahul Reddy Kasarla² and Sruthi Reddy Thummala³

¹Professor and Head, Department of Microbiology, Universal College of Medical Sciences, Bhairahawa, Nepal
²Consultant Orthopaedic Surgeon, Medivison Super Speciality Hospital, Hyderabad, India
³Assistant Professor, Department of Obstetrics & Gynaecology, Gandhi Medical College, Hyderabad, India

*Corresponding Author: Rajeshwar Reddy Kasarla, Professor and Head, Department of Microbiology, Universal College of Medical Sciences, Bhairahawa, Nepal.

Received: September 26, 2022; Published: September 28, 2022

Introduction

The discovery of hybridoma technology Kohler & Milstein for the production of monoclonal antibodies (1975) revolutionized Medicine and biological sciences by enabling the use of highly specific monoclonal antibodies in basic research, diagnostic applications, and therapeutic molecules. Antibody engineering is a new area of biotechnology which combines molecular biology and recombinant protein production [1].

References

1. Saeed AFUH., et al. “Antibody engineering for pursuing a healthier future”. Frontiers in Microbiology 8 (2017): 495.
2. Jennifer Maynard and George Georgiou. “Antibody engineering”. Annual Review of Biomedical Engineering 2 (2000): 339-376.
3. Ledsgaard L., et al. “Basics of antibody phage display technology”. Toxins (Basel)6 (2018): 236.
4. Asaadi Y., et al. “A comprehensive comparison between camelid nanobodies and single chain variable fragments”. Biomarker Research 9 (2021): 87.
5. Wesolowski J., et al. “Single domain antibodies: promising experimental and therapeutic tools in infection and immunity”. Medical Microbiology and Immunology 3 (2009): 157-174.
6. Saunders KO. “Conceptual Approaches to modulating antibody effector functions and circulation half-life”. Frontiers in Immunology 10 (2019): 1296.
7. Karen J Vincent and Mauro Zurini. “Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates”. Biotechnology Journal 12 (2012).
8. Sliwkowski MX and Mellman I. “Antibody therapeutics in cancer”. Science 341 (2013): 1192-1198.
9. Schaefer W., et al. “Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry”. MAbs1 (2016): 49-55.
10. Beck A., et al. “Strategies and challenges for the next generation of antibody-drug conjugates”. Nature Reviews Drug Discovery 16 (2017): 315.
11. Patrick Chames and Daniel Baty. “Antibody engineering and its applications in tumor targeting and intracellular immunization”. FEMS Microbiology Letters 189 (2000): 1-8.

Citation

Citation: Rajeshwar Reddy Kasarla., et al. “Antibody Engineering".Acta Scientific Biotechnology 3.5 (2022): 31-32.

Copyright

Copyright: © 2022 Rajeshwar Reddy Kasarla., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.